Articles
Matrix Metalloproteinase inhibitor, CTS-1027, attenuates liver injury and fibrosis in the bile duct-ligated mouse. Kahraman A, Bronk SF, Cazanave S, Werneburg NW, Mott JL, Contreras PC and Gores GJ. Hepatology Research 2009; 39: 805-813.
Posters
Presented at EASL 2010:
Randomized, Placebo-Controlled, Double-Blind, Dose Response (RPCDBDR) Trial of CTS-1027, An Inhibitor of Matrix Metalloproteases (MMPs), in Patients With HCV Who Had Failed Prior Therapies. Pockros PJ, Gordon SC, McCullough A, Charlton M, Bzowej N, Vierling J, Bansal MB, Yoffe B, Everson G, Huyghe M, Fox A, Mento S, Bohm O, Plouffe B, Dillon P, Cross R, Shiffman ML.
Presented at AASLD 2007:
CTS-1027, a potent MMP inhibitor, Protects Against TNFα- and α-Fas-Induced liver injury. Contreras PC, Valentino K.
Articles
Clinical Trial: Efficacy and Safety of Oral PF-03491390, a pancaspase inhibitor – a Randomized Placebo-controlled Study in Patients with Chronic Hepatitis C. Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M and Burgess G. Aliment Pharmacol Ther. 2010; 31:969-978.
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA. Hepatology 2007; 46(2):324-9.
Orally-administered caspase inhibitor PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. Ueno Y, Ohmi T, Yamamoto M, Kato N, Moriguchi Y, Kojima M, Shimozono R, Suzuki S, Matsuura T, Eda H. J Pharmacol Sci. 2007 Oct; 105(2):201-5. Epub 2007 Oct 6.
A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia. Hoglen NC, Anselmo DM, Katori M, Kaldas M, Shen XD, Valentino KL, Lassman C, Busuttil RW, Kupiec-Weglinski JW, Farmer DG. Liver Transpl. 2007 Mar;13(3):361-6.
Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren FG, Oliver LK, Rosen CB, Gores GJ. Am J Transplant. 2007 Jan;7(1):218-25.
First-in-class pan caspase inhibitor developed for the treatment of liver disease. Linton SD, Aja T, Armstrong RA, Bai X, Chen LS, Chen N, et al. J Med Chem. 2005 Nov 3;48(22):6779-82.
Caspase Inhibition Improves Ischemia-Reperfusion Injury After Lung Transplantation. Quadri SM, Segall L, de Perrot M, Han B, Edwards V, Jones N, Waddell TK, Liu M, Keshavjee S. Am J Transplant. 2005; 5:292-9.
Characterization of IDN-6556 (3-{2-(2-tert-Butyl-phenylaminooxaly)-amino]-propionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic Acid): a Liver-Targeted Caspase Inhibitor. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, Contreras PC. J Pharmacol Exp Ther. 2004 May;309(2):634-40. Epub 2004 Jan 23.
The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. J Pharmacol Exp Ther. 2004 Mar; 308(3):1191-6. Epub 2003 Nov 14.
First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN6556, improves liver enzymes. Valentino KL, Gutierrez M, Sanchez R, Winship MJ, Shapiro DA. Int J Clin Pharmacol Ther. 2003 Oct;41(10):441-9.
The caspase inhibitor IDN-6556 prevents caspase activation and apoptosis in sinusoidal endothelial cells during liver preservation injury. Natori S, Higuchi G, Contreras P, Gores GJ. Liver Transpl. 2003 Mar;9(3):278-84.
Posters
Presented at EASL 2010:
PF-03491390 Pan-Caspase Inhibitor Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis (NASH). Barreyro J, Holod S, Finocchietto PV, Avagnina A, Camino AM, Biondo CM, Aquino JB, Carreras MC, Poderoso J, Gores G.J.
Abstracts
Presented at AASLD 2007:
PF-03491390 Inhibits Liver Fibrosis in Patients with Chronic Hepatitis C Virus Infection via Suppressions of Pro-apoptotic Caspase-activation. Burgess G, Colman P, Engmann E, Bantel H, Soni PN. Hepatology 2007; 46(4):818A.